Recent advances in the trifluoromethylation methodology and new CF3-containing drugs.

This review provides a brief assessment of the methodological field of trifluoromethylation and its possible impact on the development of new CF 3 -containing pharmaceuticals. Structural aspects of five new drug-candidates, [tafenoquine (aromatic CF 3 ), roniciclib (heteroaromatic CF 3 ), BAY-38-7271 (aliphatic CF 3 ), sonidegib (O CF 3 ) and navitoclax (S-CF 3 )] currently under the development in phase II and III clinical studies, and their biological properties, therapeutic area and synthesis are critically discussed. [ABSTRACT FROM AUTHOR]